According to a recent LinkedIn post from Databricks, pharmaceutical major AstraZeneca is using the Databricks platform to embed data visualizations directly into collaboration tools such as Microsoft Teams. The post describes an approach that replaces table-heavy interfaces with governed, portable visuals designed to speed decision-making within existing workflows.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights the use of Agent Bricks, Unity Catalog Functions, and Vega-Lite to generate these visualizations in a controlled environment. Early internal feedback cited in the post suggests up to 90% faster time to insight, three to four times more questions per session, and roughly double adoption among non-technical users.
For investors, the post implies that Databricks’ tooling may be gaining traction in complex, highly regulated enterprise settings such as global pharma. If such use cases scale across AstraZeneca and similar customers, this could support higher platform stickiness, expand workloads on Databricks, and potentially enhance the company’s competitive position in data and AI infrastructure.
The emphasis on improving accessibility for non-technical users may also indicate a strategy to broaden the addressable user base inside large accounts. Over time, successful deployment in collaboration environments like Teams could translate into larger consumption-based revenues and increased cross-sell opportunities across Databricks’ ecosystem.